Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...
The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...